Rabies virus vaccine as an immune adjuvant against cancers and glioblastoma: new studies may resurrect a neglected potential
Clin. transl. oncol. (Print)
; 19(7): 785-792, jul. 2017.
Article
in English
| IBECS
| ID: ibc-163433
Responsible library:
ES1.1
Localization: BNCS
ABSTRACT
To review the literature about the use of Rabies Virus-Vaccine (RV-V) as an anticancer immunotherapeutic modality in the light of recent findings. The literature search in relevant databases with the following key words Rabies virus, cancer, remission. Remissions occured following RV-V injections in patients with cervical cancer and melanoma. Pilot clinical studies showed that RV-V injections enhanced survival in glioblastoma patients, which is supported by findings in GL261 mouse glioma model. If public health studies demonstrate protective role of RV-V against certain types of cancers, it can be benefitted as a novel immune adjuvant in clinic (AU)
RESUMEN
No disponible
Search on Google
Collection:
National databases
/
Spain
Health context:
Sustainable Health Agenda for the Americas
/
SDG3 - Health and Well-Being
/
Neglected Diseases
Health problem:
Goal 9: Noncommunicable diseases and mental health
/
Target 3.3: End transmission of communicable diseases
/
Target 3.4: Reduce premature mortality due to noncommunicable diseases
/
Neglected Diseases
/
Zoonoses
Database:
IBECS
Main subject:
Rabies Vaccines
/
Glioblastoma
/
Immunotherapy
/
Neoplasm Regression, Spontaneous
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Clin. transl. oncol. (Print)
Year:
2017
Document type:
Article
Institution/Affiliation country:
Maastricht University Medical Centre/The Netherlands
/
Memorial Hospital/Turkey
/
Neuro-Academy Research Group/Turkey